This edition of the Life Science, Health & Wellness TechVision Opportunity Engine (TOE) encompasses latest advances across life sciences, health and wellness. The TOE include innovations related to pain management, COVID-19 treatment, and biomarker platforms. It also includes innovations related to rare disease management, bioluminescence, obesity management, and cell and gene therapies.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nano medicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Table of Contents
1. Breakthrough Innovations Fueling Life Sciences, Health & Wellness
- Non-opioid-based Pain Reliever for Bone Metastases
- Gene Therapy-based Treatment for Chronic Pain
- A Non-narcotic Pain Reliever for Migraine
- Patch-based Technology for Pain Relief
- Intravenous Treatment for Migraine Relief in Launch Stage
- Partially Invasive Nerve Stimulator to Solve Pain
- Neurostimulator for the Treatment of Fibromyalgia
- A Smart Wearable Device for Pain Relief
- Bioluminescence to Detect Early Tooth Decay
- Drug Repurposing as a Novel Treatment for Triple Negative Breast Cancer
- An In Vitro Diagnostic Test for Diagnosis of COVID-19
- CE Marking Grants European Approval for COVID-19 Diagnostic Test
- Promising Novel Multi-specific Immuno-oncology Drug in Development
- Proprietary Multi-Specific Antibody Discovery and Engineering Platform
- Beta-3 Agonist Drug as a Treatment for Overactive Bladder
- Vibegron Awaiting FDA Approval After Successful NDA Application
- Novel Biodegradable Intracameral Ophthalmic Implant
- FDA Approves Drug Implant for Open Angle Glaucoma And Ocular Hypertension
- Uncovering Mechanism of an Existing Obesity Drug
- GLP-1 Receptors and GABA Neurons as New Drug Targets for Obesity
- Novel Technology Platform Based on T-Cell Engagers and CAR-Ts
- Development of Novel Immunotherapies Against Solid Tumor Treatment
- Targeting Specific Proteases for Treatment of COVID-19
- Potential Treatment and Drug Target Against Coronaviruses
- Novel Drug Candidates Designed to Combat Bacterial Infections
- Novel Drug Candidates Designed to Combat Bacterial Infections and Rare Diseases
- Drug Delivery through the Cell’s Natural Communications System
- Circulating Tumor Cells Detection through a Novel Technology
- Insulin Producing Transplantable Stem Cell Technology
- Controlled and Prolonged Release of Local Medication
- Severe Dengue Prediction Assay
- Personalized Biomarker Diagnostics
- Gene Therapy for Muscular Wasting
- Liposome-based Pulmonary Drug Delivery System
- Industry Influencers
2. Key Contacts
